HBM (HKG:2142) unit Nona Biosciences US signed a license agreement with Visterra to support the development of new treatments for immune-related and autoimmune diseases, a Thursday Hong Kong bourse filing said.
The collaboration will use Nona's HCAb Harbour Mice platform, which produces fully human antibodies that can be used for next-generation biotherapeutics, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.